Pierrepont Therapeutics develops targeted treatments for primary mitochondrial diseases.
Pierrepont Therapeutics has raised $500K in total funding. The most recent round was Seed. The last funding was announced in April 2024.
Pierrepont Therapeutics's investors include Mito Fund.
Pierrepont Therapeutics is headquartered in Pittsburgh, United States.
Pierrepont Therapeutics develops targeted treatments for primary mitochondrial diseases.
Pierrepont Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Pierrepont Therapeutics — Funding & Investors." VCBacked, April 4, 2024, https://www.vcbacked.co/company/pierrepont-therapeutics. Accessed August 2, 2026.
VCBacked. (2024). Pierrepont Therapeutics — Funding & Investors. Retrieved August 2, 2026, from https://www.vcbacked.co/company/pierrepont-therapeutics
{{cite web |title=Pierrepont Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/pierrepont-therapeutics |website=VCBacked |access-date=August 2, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated